loading

Warum fällt Brainstorm Cell Therapeutics Inc-Aktie (BCLI)?

Wir haben während der Handelssitzung 2024-12-19 einen Rückgang der Aktie Brainstorm Cell Therapeutics Inc (BCLI) um 7.56% festgestellt. Obwohl dies auf normale Volatilität oder verschiedene interne und externe Faktoren zurückzuführen sein kann, beachten Sie bitte, dass wir die Situation aktiv beobachten und so schnell wie möglich zeitnahe Updates bereitstellen!
2023-09-28:

Shares of Brainstorm Cell Therapeutics Inc. (BCLI) were down 47.73% to $0.20 after the company announced the FDA Advisory Committee voted that NurOwn did not demonstrate substantial evidence of effectiveness for treatment of mild to moderate ALS.

https://www.benzinga.com/news/earnings/23/09/34981141/crude-oil-moves-lower-carmax-posts-downbeat-earnings

2023-09-25:

Brainstorm Cell Therapeutics Inc. (BCLI) fell 47.57% to $0.4277 after the FDA said it does not believe there is sufficient evidence to support that any of the assessed biomarkers for the company's ALS therapy is reasonably likely to predict clinical benefit.

https://www.benzinga.com/news/23/09/34873722/why-brainstorm-cell-therapeutics-shares-are-trading-lower-by-33-here-are-other-stocks-moving-in-mond

$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
Kapitalisierung:     |  Volumen (24h):